Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Kymab to present data on its lead immuno-oncology antibody, demonstrating strong potential for inhibiting tumour growth

Kymab Group Ltd
Posted on: 08 Nov 17

Kymab to present data on its lead immuno-oncology antibody, demonstrating strong potential for inhibiting tumour growth

Cambridge, UK, 8 November 2017:   Kymab Group Limited ("Kymab"), a biopharmaceutical company developing fully human monoclonal antibody therapeutics, today announces that data on KY1044 (a novel anti-ICOS antibody), the lead candidate in its immuno-oncology pipeline, will be presented at the Society for Immunotherapy of Cancer's (SITC) 32 nd  Annual Meeting.  The data, based on non-human tumour models, suggest KY1044 strongly inhibits tumour growth, including complete remissions, in a number of cancer models both as a monotherapy and acting synergistically in combination with checkpoint inhibitors such as anti-PD-L1.

KY1044 is a fully human antibody that allows the immune system to better recognise and kill tumours. KY1044 has a dual mode of action: stimulating immune cells which are fighting the tumour while also killing a type of cell known as T regulatory cells (Tregs) which are often found in tumours and which inhibit the immune response and prevent or slow the activity of anti-tumour T cells.  Intratumoural Tregs express a high level of ICOS on their surface.  Removing these cells using KY1044 allows the immune system to work more effectively at killing cancer cells.

"We are excited to unveil KY1044, the lead development product in our growing immuno-oncology franchise, where we are focusing on enabling the patient's own immune system to boost its intrinsic ability to eradicate tumours," says Dr. David Chiswell CEO of Kymab. "We believe that KY1044 has considerable potential and will provide patient benefits in a significant number of cancer indications."

Kymab plans to file an investigational new drug application for KY1044 in late 2018 and commence clinical trials in 2019. KY1044 will be evaluated in cancer patients both as a monotherapy and in combination with other immunotherapies.

The SITC meeting is being held on 08-12 November 2017 at the Gaylord National Hotel & Convention Center, in Maryland, USA.   The Kymab poster will be presented on Saturday, November 11, 2017 at 12.30 - 14.00 and 18.00 to 20.00.  Please see below for more information.  

###END ###

For further information contact:


David Chiswell, Chief Executive Officer

Anne Hyland, Chief Financial Officer

Tel: +44 (0)1223 833 301, Email:

Consilium Strategic Communications:

Mary-Jane Elliott / Jessica Hodgson / Laura Thornton

Tel: +44 (0) 20 3709 5700, Email: 

Notes to Editors

About Kymab's SITC Poster

Title: KY1044, a novel anti-ICOS antibody, elicits long term in vivo anti-tumour efficacy as monotherapy or in combination with immune checkpoint inhibitors.
Poster Number: 288
Date: Saturday, November 11, 2017
Session Time: 12.30 - 14.00 and 18.00 to 20.00
Location: Prince George's Exhibition Hall DE, Gaylord National Hotel & Convention Center, in Maryland, USA

The Kymab poster will be available from 11 November 2017 at the following URL:

About Kymab

Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.

Kymab's platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.

Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. Kymab was founded in 2010 and has raised over US$220m of equity financing. It has an experienced management team with a successful track record in drug discovery and development and a broad pipeline of therapeutic antibody programmes in immune-oncology, auto-immunity, haematology, infectious disease and other areas.

For more information please see

Kymab is a trademark of Kymab Limited .

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Kymab Group Ltd via GlobeNewswire

Last updated on: 09/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.